- Home
- NRSN
as 12-18-2024 1:40pm EST
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
Upcoming Earnings Alert:
Get ready for potential market movements as NeuroSense Therapeutics Ltd. NRSN prepares to release earnings report on 24 Dec 2024.
| Founded: | 2017 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 17.8M | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 312.6K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.61 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.51 - $2.33 | Next Earning Date: | 12-24-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest NeuroSense Therapeutics Ltd. News
NRSN Breaking Stock News: Dive into NRSN Ticker-Specific Updates for Smart Investing
PR Newswire
7 days ago
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC
MT Newswires
12 days ago
NeuroSense Therapeutics Files Prospectus for Secondary Stock Sale
PR Newswire
14 days ago
NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS
PR Newswire
16 days ago
NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price
PR Newswire
a month ago
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND
MT Newswires
2 months ago
Neurosense, FDA to Meet Nov. 6 to Discuss Design of Amyotrophic Lateral Sclerosis Treatment Trial; Shares Rise
PR Newswire
2 months ago
NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission
Benzinga
2 months ago
EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission
Compare NRSN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NRSN NeuroSense Therapeutics Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.